Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
Anti-S100A4 Protein Antibody
Applicable field (uses covered by this announcement)
Disease researchDrug Discovery Research
Launch date29 July 2026 (actual)
What the company reported numerically
Quantitative Effects
Highly sensitive detection enables accurate measurement even at extremely low concentrations.
Relationship between the counterparty and the company
Perseus Proteomics Inc.4882
Relationship with the Company
The company provides research antibodies and reagents to universities, research institutions and companies.
Offering price
The company’s website is referenced, but no price is provided.
Impact on Business Performance
The company states that it will work to expand its earnings base and achieve sustained growth in corporate value, but no specific impact on financial performance is provided.
The company does not address Contract Value.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Anti-S100A4 Protein Antibody |
| Relationship with the Company | The company provides research antibodies and reagents to universities, research institutions and companies. |
| Offering price | The company’s website is referenced, but no price is provided. |
| Launch date | 29 July 2026 (actual) |
| Applicable area | Disease research, Drug Discovery Research |
| Quantitative Effects | Highly sensitive detection enables accurate measurement even at extremely low concentrations. |
| Impact on Business Performance | The company states that it will work to expand its earnings base and achieve sustained growth in corporate value, but no specific impact on financial performance is provided. |
Items this document does not state (11)
CounterpartyCounterparty overviewContract ValueContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the lineup of research antibody reagents and address the diverse needs of researchers.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.